Walleye Capital’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Walleye Capital’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26,270	Closed	-$3.42K	–	5365
2024 Q4	$3.42K	Sell	26,270 -141,858	-84%	-$17.8K	﹤0.01%	4635
2024 Q3	$18.4K	Hold	168,128	–	–	﹤0.01%	4829
2024 Q2	$16.8K	Hold	168,128	–	–	﹤0.01%	5145
2024 Q1	$25.2K	Hold	168,128	–	–	﹤0.01%	4863
2023 Q4	$25.2K	Buy	+168,128	New	+$27.2K	﹤0.01%	4429

Walleye Capital's BLACR Position: Q1 2025 in Review

Walleye Capital sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 26,270 shares — an estimated $3.42K sold.

Walleye Capital first reported a position in BLACR in Q4 2023 and held it in 5 quarters. The position peaked at $25.2K in Q1 2024. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Walleye Capital reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 26,270 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $3.42K.
Walleye Capital first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q4 2023 and held it in 5 quarters.
Walleye Capital's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $25.2K in Q1 2024.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.